esophageal cancer
The agency is considering whether to limit the indications of Keytruda, Opdivo, and Tevimbra to PD-L1-positive patients amid testing uncertainties.
FDA Expert Panel to Consider Limiting Gastric, Esophageal Cancer Immunotherapies to PD-L1 Expressors
The ODAC will weigh risk-benefit analyses from the FDA and sponsors on Keytruda, Opdivo, and Tevimbra when given with chemo in all-comers and in PD-L1-positive subgroups.
Lucid Diagnostics Partners With Front Line Mobile to Promote Esophageal Cancer Test
Working with the first responder medical care provider, Lucid is planning high-volume testing events among firefighters and other frontline workers with elevated risk.
Lucid Diagnostics' Esophageal Precancer Test Sales Spike in Q2
The firm's revenues, all from the EsoGuard DNA screening test, increased to $976,000 in Q2 compared to $159,000 in the same quarter last year.
The researchers believe the chemosensitivity signatures generated with this approach from human and dog samples could be broadly applicable across cancer types.